Triple therapy and incidence of de novo cancer in renal transplant recipients

E. O. Kehinde, A. Petermann, J. D. Morgan, Z. A. Butt, P. K. Donnelly, P. S. Veitch, P. R F Bell

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma.

Original languageEnglish
Pages (from-to)985-986
Number of pages2
JournalBritish Journal of Surgery
Volume81
Issue number7
DOIs
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Kidney Neoplasms
Prednisolone
Cyclosporine
Azathioprine
Incidence
Therapeutics
Transplants
Kidney
Neoplasms
Nifedipine
Immunosuppressive Agents
Transplant Recipients
Transplantation
Maintenance
Prospective Studies
Carcinoma

ASJC Scopus subject areas

  • Surgery

Cite this

Kehinde, E. O., Petermann, A., Morgan, J. D., Butt, Z. A., Donnelly, P. K., Veitch, P. S., & Bell, P. R. F. (1994). Triple therapy and incidence of de novo cancer in renal transplant recipients. British Journal of Surgery, 81(7), 985-986. https://doi.org/10.1002/bjs.1800810718

Triple therapy and incidence of de novo cancer in renal transplant recipients. / Kehinde, E. O.; Petermann, A.; Morgan, J. D.; Butt, Z. A.; Donnelly, P. K.; Veitch, P. S.; Bell, P. R F.

In: British Journal of Surgery, Vol. 81, No. 7, 1994, p. 985-986.

Research output: Contribution to journalArticle

Kehinde, EO, Petermann, A, Morgan, JD, Butt, ZA, Donnelly, PK, Veitch, PS & Bell, PRF 1994, 'Triple therapy and incidence of de novo cancer in renal transplant recipients', British Journal of Surgery, vol. 81, no. 7, pp. 985-986. https://doi.org/10.1002/bjs.1800810718
Kehinde EO, Petermann A, Morgan JD, Butt ZA, Donnelly PK, Veitch PS et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. British Journal of Surgery. 1994;81(7):985-986. https://doi.org/10.1002/bjs.1800810718
Kehinde, E. O. ; Petermann, A. ; Morgan, J. D. ; Butt, Z. A. ; Donnelly, P. K. ; Veitch, P. S. ; Bell, P. R F. / Triple therapy and incidence of de novo cancer in renal transplant recipients. In: British Journal of Surgery. 1994 ; Vol. 81, No. 7. pp. 985-986.
@article{3c93c2fd6d7944ec8cad86f9d14a15ce,
title = "Triple therapy and incidence of de novo cancer in renal transplant recipients",
abstract = "Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma.",
author = "Kehinde, {E. O.} and A. Petermann and Morgan, {J. D.} and Butt, {Z. A.} and Donnelly, {P. K.} and Veitch, {P. S.} and Bell, {P. R F}",
year = "1994",
doi = "10.1002/bjs.1800810718",
language = "English",
volume = "81",
pages = "985--986",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Triple therapy and incidence of de novo cancer in renal transplant recipients

AU - Kehinde, E. O.

AU - Petermann, A.

AU - Morgan, J. D.

AU - Butt, Z. A.

AU - Donnelly, P. K.

AU - Veitch, P. S.

AU - Bell, P. R F

PY - 1994

Y1 - 1994

N2 - Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma.

AB - Some 27 (5·5 per cent) of 492 renal transplant recipients developed de novo cancer between January 1975 and December 1991. Patients administered triple therapy of prednisolone, cyclosporin A and azathioprine had a significantly higher incidence of cancer (seven of 40 patients; 17·5 per cent) than those given prednisolone with cyclosporin (14 of 319; 4·4 per cent) and azathioprine with prednisolone (six of 133; 4·5 per cent) (P= 0·005). In a prospective study between January 1989 and December 1992, 110 renal transplant patients were randomized into three immunosuppressive regimens at the time of transplantation. The incidence of cancer in patients receiving low‐dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high‐dose cyclosporin and prednisolone none of 23 and in those administered high‐dose cyclosporin, nifedipine and prednisolone one of 29. The addition of azathioprine to ongoing maintenance cyclosporin and prednisolone therapy is useful in a subgroup of patients with graft dysfunction, but there are possibly higher risks in the development of de novo carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0028244603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028244603&partnerID=8YFLogxK

U2 - 10.1002/bjs.1800810718

DO - 10.1002/bjs.1800810718

M3 - Article

C2 - 7922092

AN - SCOPUS:0028244603

VL - 81

SP - 985

EP - 986

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 7

ER -